CANF (CANF) Stock Price & Analysis
CANF (CANF) fell 1.24% to USD 3.19 as of July 25, 2026 at 07:26 UTC, according to Nexqual real-time market data.
CANF last closed at USD 3.23; the session ranged USD 3.15–3.3 on volume of 30,876 shares. Market capitalization is $6.83M, with a 52-week range of USD 2.56–20.2 (ASE). Source: Nexqual, July 25, 2026 at 07:26 UTC.
Key Statistics (as of July 25, 2026 at 07:26 UTC)
| Price | USD 3.19 |
|---|---|
| Change | ▼ 1.24% (down) |
| Previous Close | USD 3.23 |
| Open | USD 3.2 |
| Day Range | USD 3.15 – 3.3 |
| 52-Week Range | USD 2.56 – 20.2 |
| Volume | 30,876 shares |
| Market Cap | $6.83M |
| Exchange | ASE |
Technical Analysis (CANF)
Nexqual's technical model rates CANF "SELL" based on 2 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 07:26 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 47.27 (neutral) |
| vs SMA50 | Below (USD 3.24) |
| MACD | 0.01 (positive) |
Analyst Ratings (CANF)
Wall Street analysts rate CANF "None" based on 1 analysts, with a mean price target of USD 8 (range USD 8–8), per Nexqual as of July 25, 2026 at 07:26 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 8 |
| High Target | USD 8 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (CANF)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-06-30 | USD 0 vs est -2.4 ▲ beat |
Source: Nexqual, July 25, 2026 at 07:26 UTC.
Financials & Fundamentals (CANF)
| Total Revenue | $405,000 |
|---|---|
| Revenue Growth (YoY) | -43.30% |
| Gross Margin | +100.00% |
| Operating Margin | -2488.67% |
| Profit Margin | +0.00% |
| ROE | -178.24% |
| Debt / Equity | 1.27 |
| Current Ratio | 3.46 |
| Total Cash | $8.54M |
| Total Debt | $71,000 |
| Free Cash Flow | $-4.99M |
Source: Nexqual, July 25, 2026 at 07:26 UTC.
Financial Health Score (CANF)
Nexqual rates CANF's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 07:26 UTC.
| Growth | Critical — Revenue -40% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $9M cash, no debt |
| Cash Flow | Weak — FCF negative: -$5M, burning cash |
| Efficiency | Critical — ROE -178%, ROA -66.7% |
Ownership (CANF)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +6.55% |
| Shares Outstanding | 2.14M |
| Float | 2.14M |
| Short % of Float | +5.17% |
Source: Nexqual, July 25, 2026 at 07:26 UTC.
Leadership (CANF)
CANF is led by Motti Farbstein (age 61), CEO, CFO, Financial & Operating Officer, per Nexqual as of July 25, 2026 at 07:26 UTC.
| CEO, CFO, Financial & Operating Officer | Motti Farbstein (age 61) |
|---|---|
| Founder, Chief Scientific Officer & Executive Chairperson | Pnina Fishman (age 77) |
| Vice President of Business Development | Sari Fishman (age 53) |
Major Backers & Investors (CANF)
Notable institutional backers of CANF include Sabby Management, LLC, Citadel, Rhumbline Advisers, according to Nexqual as of July 25, 2026 at 07:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Sabby Management, LLC | 1.99% |
| Citadel | 1.59% |
| Rhumbline Advisers | 0.98% |
| HRT Financial LP | 0.9% |
| Virtu Financial LLC | 0.6% |
| Citigroup Inc. | 0.26% |
Source: Nexqual, July 25, 2026 at 07:26 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BLRX | BioLineRx Ltd. | USD 2.82 | ▼ 1.05% |
| HEPA | Hepion Pharmaceuticals, Inc. | USD 0.05 | ▲ 1.89% |
| CFOR | OpGen, Inc. | USD 18 | ▼ 10% |
| CETX | Cemtrex Inc. | USD 2.7 | ▼ 11.76% |
| RDHL | Redhill Biopharma Ltd. | USD 0.63 | ▼ 7.55% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:26 UTC. This page is informational and not investment advice.